Physician profile
Eric Olson
NPI 1275531865
$3,829.77
in general payments reported to CMS, 2019-2025
13 companies · $761 in 2025
The $761 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $15.82 · 2021: $484 · 2022: $440 · 2023: $557 · 2024: $989 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,227 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,226.96 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $779.65 | 2019-2024 | Tremfya |
| Abbvie INC. | $756.72 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $432.67 | 2022-2025 | Libtayo, Dupixent |
| Lilly USA, LLC | $380.16 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $328.06 | 2023-2025 | Sotyktu |
| Ucb, INC. | $283.24 | 2019-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $250.71 | 2021-2022 | |
| Genzyme Corporation | $212.52 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $205.80 | 2019 | |
| Incyte Corporation | $95.69 | 2023-2024 | Opzelura |
| Pfizer INC. | $47.56 | 2022 | |
| Amgen INC. | $38.47 | 2024 | Otezla |
| Novartis Pharmaceuticals Corporation | $18.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.